Parabilis Medicines (NASDAQ:PBLS) Reaches New 52-Week High – Here’s What Happened

Posted by Brenda Bartman on Sep 19th, 2026

Parabilis Medicines, Inc. (NASDAQ:PBLS – Get Free Report)’s stock price reached a new 52-week high on Thursday . The stock traded as high as $41.98 and last traded at $41.98, with a volume of 271135 shares. The stock had previously closed at $36.88.

Wall Street Analysts Forecast Growth

PBLS has been the subject of several recent research reports. Lifesci Capital raised Parabilis Medicines to a “strong-buy” rating in a research note on Monday, July 6th. Leerink Partners assumed coverage on shares of Parabilis Medicines in a research report on Monday, July 6th. They set an “outperform” rating and a $40.00 target price on the stock. Zacks Research raised shares of Parabilis Medicines to a “hold” rating in a report on Tuesday, July 7th. Weiss Ratings initiated coverage on shares of Parabilis Medicines in a research report on Friday, September 4th. They issued a “sell (d)” rating for the company. Finally, Guggenheim started coverage on shares of Parabilis Medicines in a research note on Monday, July 6th. They set a “buy” rating and a $40.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $41.67.

Check Out Our Latest Research Report on PBLS

Parabilis Medicines Stock Up 2.1%

The company has a 50 day moving average of $35.93.

Parabilis Medicines (NASDAQ:PBLS – Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($2.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($2.16). The business had revenue of $0.15 million for the quarter. On average, equities research analysts predict that Parabilis Medicines, Inc. will post -2.05 EPS for the current fiscal year.

Institutional Investors Weigh In On Parabilis Medicines

Several large investors have recently modified their holdings of the company. Persistent Asset Partners Ltd acquired a new position in Parabilis Medicines in the second quarter valued at $113,000. Alyeska Investment Group L.P. acquired a new stake in Parabilis Medicines during the 2nd quarter worth about $274,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Parabilis Medicines during the 2nd quarter worth about $526,000. WINTON GROUP Ltd bought a new position in shares of Parabilis Medicines in the 2nd quarter worth about $955,000. Finally, Squarepoint Ops LLC bought a new position in shares of Parabilis Medicines in the 2nd quarter worth about $1,327,000.

About Parabilis Medicines

(Get Free Report)

Parabilis Medicines Inc is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc is based in CAMBRIDGE, Mass.